- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07937410
Chronic Subdural Hematoma Recurrence (cSDH RCT)
The Effect of Dextrose 5% in 0.225% Sodium Chloride (D5 ¼NS) on Postoperative Chronic Subdural Hematoma Size and Recurrence Rate: a Prospective, Randomized, Double-blinded, Placebo Controlled Clinical Trial
How can investigators improve recurrence rates of chronic subdural hematomas to reduce need for surgical intervention? Study investigators hypothesize that Dextrose 5% in 0.225% Sodium Chloride (D5 ¼NS) will increase the intracellular brain volume and water content post-operatively, reducing the residual subdural space that is created by evacuation of the chronic subdural hematoma (CSDH), and that this, in turn, will reduce the hematoma volume that will then potentially lead to improved functional outcomes, reduced hospitalization time as well as the reduced rate of symptomatic recurrence requiring redo surgery.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
The proposed study is a randomized, placebo controlled clinical trial to investigate the effects of D5 ¼NS (treatment) vs. NS (placebo) on residual cSDH volume after surgical drainage via a craniotomy or burr holes.
Participants in the study will be adult patients who had presented with imaging evidence (based on non-contrast head CT) of cSDH requiring surgical evacuation (craniotomy or burr holes). Patients in this study will receive either 5% dextrose ¼Normal Saline (treatment) or Normal Saline (placebo) for 24h after surgery. The study group assignment will be performed based on randomization process prior to the surgery. All the patients will be undergoing a head CT without contrast imaging at 24h after surgery. The residual hematoma volume will be calculated based on XYZ/2 method as previously described (Sucu et al., 2005).
The bedside nursing staff will be provided with either the placebo or D5 ¼NS solutions from the pharmacy in an opaque bag to be administered to the patient after the randomization process has taken place. The procedure for the placebo and treatment solution administration is the same as the standard intravenous fluid administration procedure except the fact of an opaque covering and maintenance of the blinding throughout the process. The bedside nursing staff will administer the intravenous fluid. The infusion rate, as stated, will be 100 cc/h for 24h after SDH evacuation surgery at which time a standard of care head CT without contrast will be obtained. This will be a double-blinded study where blinding will be achieved via the prerandomized enrollment log. Participants signing the consent will be enrolled based on time of enrollment and study ID will be prelinked to a study group of normal saline (placebo) or D51/4NS solution. Pharmacy who will be documenting the treatment allocation and will be issuing the IV fluid for each of the patients will be maintaining the blinding status. The pharmacy staff and coordinator will be the only individuals holding the blinding key which will be released at the official end of the study after all the datapoints have been gathered for all the participants. Additionally, the patients will have basic metabolic panel (BMP as standard of care ) labs drawn every 12 hours during the 24 hour treatment period to assess the electrolyte status and any adverse reactions. The PI and all other study team members, other than the randomizing coordinator, will remain blinded. The unblinded coordinator will not perform any clinical assessments and will not share blinding information with any other team members.
Symptomatic recurrence rates requiring redo surgery within a 90-day period (+/- 7 days) after the initial surgery will be identified via the chart review of each individual study participant.
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 2
- Fas 1
Kontakter och platser
Studiekontakt
- Namn: Jordan Darden, PhD
- Telefonnummer: 540-529-7792
- E-post: jadarden@carilionclinic.org
Studera Kontakt Backup
- Namn: Kristine Ravina, MD
- Telefonnummer: 540-224-5170
- E-post: kravina@carilionclinic.org
Studieorter
-
-
Virginia
-
Roanoke, Virginia, Förenta staterna, 24014
- Rekrytering
- Carilion Clinic
-
Kontakt:
- Jordan Darden, PhD
- Telefonnummer: 540-529-7792
- E-post: jadarden@carilionclinic.org
-
Huvudutredare:
- Eric Marvin, DO
-
Kontakt:
- Kristine Ravina, MD
- Telefonnummer: 540-224-5170
- E-post: kravina@carilionclinic.org
-
Underutredare:
- Kristine Ravina, MD
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Written and voluntarily given informed consent
- If the patient cannot give informed consent, a legally authorized representative may provide it
- Male or female 18-100
- Imaging evidence indicative of cSDH
- The neurosurgical team has determined that the patient requires surgical evacuation of the cSDH
Exclusion Criteria:
- significant/symptomatic hyperglycemia; specifically diabetic ketoacidosis or fasting blood glucose level >200 mg/dl
- Patients with significant hyponatremia (Na <130 mEq/L)
- Patients who are judged by investigators as being ineligible for participation in the study Patients with a history of relevant drug hypersensitivity Patients who receive another investigational drug shortly before acquisition of consent Women who are pregnant or breastfeeding
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Placebo-jämförare: normal saline
normal saline |
normal saline
Andra namn:
|
|
Aktiv komparator: saline with dextrose (D5 ¼NS solutions)
saline with dextrose (D5 ¼NS solutions) |
D5 ¼NS solutions
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Comparative residual CSDH volume (in mm3) measured and calculated using head CT
Tidsram: 24 hours after surgery
|
Comparative residual CSDH volume (in mm3) measured and calculated using head CT |
24 hours after surgery
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
ICU and overall hospitalization length of stay
Tidsram: duration of total hospital stay assessed for up to 6 months
|
ICU and overall hospitalization length of stay. |
duration of total hospital stay assessed for up to 6 months
|
|
Functional improvement as measured using mRS scale scores upon admission
Tidsram: follow up post surgery assessment up to 6 weeks post release
|
Functional improvement as measured using mRS scale scores upon admission, scoring from 0-6, low score with no symptoms and 6 indicating death |
follow up post surgery assessment up to 6 weeks post release
|
|
Symptomatic recurrence rates requiring redo surgery within a 90-day period (+/- 7 days) after the initial surgery
Tidsram: 90 days post surgery
|
Symptomatic recurrence rates requiring redo surgery within a 90-day period (+/- 7 days) after the initial surgery |
90 days post surgery
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Eric Marvin, DO, Carilion Clinic
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Cerebrovaskulära störningar
- Hjärnsjukdomar
- Sjukdomar i centrala nervsystemet
- Sjukdomar i nervsystemet
- Kärlsjukdomar
- Hjärt-kärlsjukdomar
- Sår och skador
- Patologiska processer
- Kronisk sjukdom
- Sjukdomsegenskaper
- Blödning
- Kraniocerebralt trauma
- Trauma, nervsystemet
- Intrakraniella blödningar
- Intrakraniell blödning, traumatisk
- Patologiska tillstånd, tecken och symtom
- Hematom, Subdural
- Hematom
- Upprepning
- Hematom, Subdural, Kronisk
- Farmaceutiska förberedelser
- Kolhydrater
- Oorganiska kemikalier
- Klorföreningar
- Kristalloidlösningar
- Isotonlösningar
- Lösningar
- Socker
- Natriumföreningar
- Hexos
- Monosackarider
- Klorider
- Saltsyra
- Saltlösning
- Glukos
- Natriumklorid
Andra studie-ID-nummer
- IRB-23-2036
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .